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Introduction 
Diabetes mellitus is characterized by elevated blood glucose levels. The estimated 
number of people with diabetes worldwide in 2017 is 425 million, the number is 
expected to increase to 642 million by 2040. Type 2 diabetes (T2D), characterized as 
multiple organ (e.g., muscle, liver, and adipose) insulin resistance (IR), makes up about 
90% of cases of diabetes.  
Recent research showed that increasing ectopic triglyceride (TG) accumulation was 
associated with IR and T2D. Adipose tissue is well known lipid storage, but has a limited 
maximal capacity to store lipids. Once beyond this limitation, excess fatty acids would 
spill over into the blood, lead to their ectopic storage in the tissues which normally 
contain only small amount of fat, such as the liver, skeletal muscle, heart, and 
pancreas[1]. Ectopic fat accumulation induces metabolic processes disruption and 
organ function impaired[2].  
Plants are abundant in biologically active molecules that play critical roles in 
pharmacolog[3]. Most of the available therapeutic agents that widely used for treating 
diabetes, natural antidiabetic products which are believed to have minimal side effects 
have been highlighted for the treatment of diabetes[4, 5]. Citrus sudachi is an 
evergreen tree that was found mainly in Tokushima Prefecture of Japan, and it has 
been demonstrated that Citrus sudachi had the capability of inhibiting the rising trend 
of blood glucose and fatty acid in human subjects[6, 7],though its mechanism has not 
been clarified yet. 
AMPK (AMP-activated protein kinase) is a fuel-sensing enzyme that plays a crucial role 
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in response to starvation by increasing AMP/ATP ratio. AMPK activated by 
phosphorylation of the threonine residue (Thr172) on its catalytic α-subunit, which 
initiates processes such as fatty acid oxidation that restore ATP, and inhibits ATP 
consumption such as triglyceride and protein synthesis, cell proliferation[8]. It is 
known that AMPK have effect on carbohydrate and lipid metabolism, it is already clear 
that the system is a major player in the development and/or treatment of obesity, 
diabetes, and other metabolic syndrome[9]. 
Peroxisome proliferator-activated receptors (PPARs) belongs to a subgroup in the 
family of nuclear hormone receptors and highly expressed in the most of metabolic 
tissues. PPARα was the first discovered PPARs and is known to contribute to oxidative 
processes including fatty acid metabolism[10]. PPARα exists in skeletal muscles and 
liver, which is closely correlated with fatty acid oxidation[11]. PPARα has been 
suggested as an important therapeutic target for metabolic diseases with 
hyperlipidemia [12]. 
 
1 Methods and Materials 
1-1 Materials 
We purchased AICAR, BML-275 and Gw6471 from Funakoshi Co., Ltd. (Tokyo, Japan), 
respectively. Other reagents were obtained from Kanto Chemical (Tokyo, Japan), Wako 
Pure Chemical (Osaka, Japan), or Tokyo Chemical Industry (Tokyo, Japan). The 
following commercially available antibodies were used: anti-AMPK (Sigma-Aldrich, St 
Louis, MO, USA); anti-sirt1 (Cell Signaling Technology Japan, K.K.); anti-Phospho-
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AMPKα (Thr172) (Cell Signaling Technology Japan, K.K.); anti-β-actin, as a loading 
control, from Cell Signaling Technology Japan, K.K.; anti-GAPDH, as a loading control, 
from Wako Pure Chemical Industries, Ltd.. 
1-2 The extract process of sudachi peel 
The extract process of Citrus sudachi peel was shown in Figure1. The sudachi peel dry 
powders were extracted with hexane at room temperature for 24hr, the residue was 
extracted with methanol again at the same condition, hexane extract part and 
methanol extract part were separated. The methanol extract was concentrated to a 
residue which was partitioned between hexane and 90% methanol. The 90% 
methanol-soluble fraction was chromatographed over Diaion HP 20 column, eluted 
with methanol and H2O solution, and then gradient and removing the sugar dissolved 
in water. 5 fractions named by hydrophobicity from M-F1 to M-F5 were obtained at 
last. 
In order to screen the function of Sudachi peel extracts, the extracts were dissolved in 
dimethyl sulfoxide (DMSO), made to different concentration. 
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Figure 1: The extraction and separation process of Citrus sudachi peels 
1-3 Cell culture and treatment 
Cell culture and differentiation was conducted as reported previously[13]. C2C12 
myoblasts, which are derived from mouse thigh muscle cell, were obtained from 
American Type Culture Collection. The C2C12 myoblasts were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 4.5 g/L D-(+)-Glucose (nacalai tesque), 
supplemented with 10% (v/v) fetal bovine serum in a humidiﬁed atmosphere with 5% 
CO2, and grown in DMEM supplemented with 2% horse serum for 1 week to be 
induced differentiation into myotubes.  
1-4 Triglyceride and non-essential fatty acid measurement  
Following to the stimulation, lipids were extracted with 2-propanol at 4°C overnight, 
and concentrations of triglyceride (TG) and NEFA (non-essential fatty acid) were 
determined by Triglyceride E-test Kit and NEFA C-test Kit (Wako Pure Chemical, Osaka, 
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Japan) according to the manufacturer's instruction, respectively. 
1-5 Oil Red O staining 
Cells were fixed with 10% formalin for 1 h, rinsed with PBS for 2 times, and stained with 
0.5% Oil Red O dye for 20 minutes. After washing again with PBS, cells were visually 
monitored by OLYMPUS microscopic observation. 
1-6 Western blotting 
After the stimulations, cells were washed with ice-cold PBS and lysed with lysis buffer 
(500 mM Tris-HCl, 10 mM NaCl, 1 mM MgCl2, 250 mM sucrose, 0.5% NP-40, 0.1 mM 
EGTA) as previously reported[14-17]. Protein expression and phosphorylation was 
detected by western blot analysis. Equal amounts of proteins were separated by 7.5% 
SDS-PAGE, and electrotransferred to PVDF membranes (Millipore, USA), and then were 
blocked with PBS solution with 1% Tween20 and 5% skim milk for 1 hr at room 
temperature. Membranes were incubated with appropriately diluted primary 
antibodies overnight at 4°C. Then incubated with the relevant secondary antibodies 
for 2 hr at room temperature. The immune complexes were visualized with the 
enhanced chemiluminescence (ECL) detection system according to the manufacturer’s 
instructions, in conjunction with ImageQuant LAS 4000 luminescent image analyzer 
(GE Healthcare, USA). Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) or β-
actin was served as an internal control protein. 
1-7 Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cells and was reverse-transcribed using the Superscript 
IITM First Strand Kit (Invitrogen). We evaluated the mRNA levels of peroxisome 
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proliferator-activated receptor alpha (PPARα) , sterol regulatory element-binding 
protein 1 (SREBP1) , peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1α) , carnitine palmitoyltransferase 1b (CPT1b) , acyl-coenzyme A oxidase 
(Aco) , medium chain acyl-coenzyme A dehydrogenase (MCAD) , mitochondrial 
transcription factor A (mtTFA) , uncoupling protein 2 (UCP2) , and housekeeping gene 
GAPDH, primer sequences are shown in Table1. Real-time PCR was performed on an 
ABI PRISM 7500 PCR System (Applied Biosystems, USA) using THUNDERBIRD SYBR 
qPCR Mix (TOYOBO, Japan). PCRs were carried out in a total of 20 μL as follows: one 
cycle at 95 °C for 1min, followed by 40 cycles of 95 °C for 15 sec, 65 °C for 30 sec and 
72 °C for 40 sec. The gene expression from each sample was analyzed in duplicates and 
normalized against GAPDH. The results are expressed as relative gene expression using 
the ΔCt method. 
GENE FORWARD PRIMER REVERSE PRIMER 
PPARΑ AGGCTGTAAGGGCTTCTTTCG GGCATTTGTTCCGGTTCTTC 
SREBP1 GGCTATTCCGTGAACATCTCCTA ATCCAAGGGCATCTGAGAACTC 
PGC1Α TTCCACCAAGAGCAAGTAT CGCTGTCCCATGAGGTATT 
CPT1B CGGAAGCACACCAGGCAGTA GCAGCTTCAGGGTTTGTCGGAATA 
ACO GCCGTCGAGAAATCGAGAACT TCTTAACAGCCACCTCGTAACG 
MCAD GAGCCTGGGAACTCGGCTTGA GCCAAGGCCACCGCAACTTT 
MTTFA GAAGGGAATGGAAAGGTAGA AACAGGACATGGAAAGCAGAT 
UCP2 CTACAAGACCATTGCACGAGAGG AGCTGCTCATAGGTGACAAACAT 
GAPDH AACACTGAGCATCTCCCTCA GTGGGTGCAGCGAACTTTAT 
Table1: Sequences of the primers used in real-time PCR 
 
1-8 Evaluation of viability 
The cell viability was evaluated by MTT ((3-(4,5-di-methylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) assay as previously described [18, 19]. 
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1-9 Statistical Analysis 
All the data are shown as the means ± standard deviation (SD). Student’s t-test was 
performed to determine the difference between two groups, and one-way ANOVA and 
post-hoc Tukey-Kramer test were performed to evaluate multiple groups. P<0.05 was 
considered statistically significant. 
 
2 Result 
2-1 The Crude sudachi peel and M-F4 reduce intracellular triglyceride level of C2C12 
cell  
Our previous study demonstrated that the peel dry powders of Citrus sudachi had the 
capability of inhibiting the rising trend of blood glucose and fatty acid in human. This 
result probably caused by increasing TG consumption in blood. 
We supposed that if the sudachi peel extract could reduce intracellular TG level in 
C2C12 cells.  
We try to find out which fraction of this crude extract cause this result. C2C12 myoblast 
were stimulated by 5 kinds of sudachi peel methanol extracts (M-F1~M-F5) (100 
μg/mL) for 24 hours, only M-F4 obviously down-regulated TG level (Fig 2A). The similar 
results were also observed from C2C12 myotubes treated with sudachi peel methanol 
extracts (Fig 2B). Consistent with TG level, the neutral lipids, cholesterol esters, and 
triglycerides, staining in C2C12 myotubes which treatment with M-F4 (Fig 2C-b) was 
lower than the control group (Fig 2C-a). We purposed to investigate the mechanism of 
this effect. 
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(A)  
 
(B) 
 
(C) 
 
Figure 2 : Crude sudachi peel extraction and M-F4 reduced intracellular triglyceride 
level in C2C12.  
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Crude sudachi peel extract reduced intracellular triglyceride level in C2C12 myoblasts 
(A) and myotubes (B) were stimulated by 5 kinds of extract (100 μg/mL) for 24 hr. The 
Oil Red O positive lipid storage in C2C12 myotubes which treatment with M-F4 (C-b) 
was lower than the control group (C-a). Data are expressed as the mean±SD. *:p < 0.05, 
**:p < 0.01 compared to vehicle control . 
2-2 M-F4 increases AMPK phosphorylation but did not alter Sirt1 expression. 
AMPK is a fuel-sensing enzyme that plays a crucial role in TG consumption for energy 
supply. To elucidate whether M-F4 exert a TG-lowering effect via AMPK, C2C12 
myotubes were treated with 100 μg/mL M-F4 for 24 hours and the protein levels were 
examined firstly. As expected, M-F4 increased the phosphorylation of AMPK in C2C12 
myotubes obviously in Western blotting (Fig 3A). BML-275 (compound C) is a potent, 
selective, and reversible ATP-competitive inhibitor of AMPK[20, 21]. 5-
aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) used as a positive 
control of AMPK activation to treatment cells[22]. In absence or presence of the 
stimulation by 15μM BML-275 and 1mM AICAR, as shown in Fig. 3A the BML-275 
prevent the phosphorylation level of AMPK increasing induced by M-F4, and AICAR 
improve this trend and had a combination impact. The p-AMPK/AMPK radio showed 
in Fig 3B also determined this opinion. In TG measurement, the TG reducing effect 
caused by M-F4 also decreasing with BML-275, and increasing by AICAR (Fig. 3C). 
Those data were consistent with previous western blotting results. In summary, the M-
F4 caused TG-lowering effect mediated by AMPK signaling pathway.  
On the contrary, as shown in Figure 3D, the protein expression level of Sirt1 did not 
significantly increased by M-F4. Sirtinol is a non-specific Sirt1 inhibitors. Same as the 
treatment by M-F4, sirtinol (25 μM) induced a statistically insignificant trend toward 
reduced triglyceride (Fig 3E), which means that Sirt1 had no substantive role in 
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reducing TG. Those datum were consistent with previous western blotting results. In 
summary, the M-F4 caused TG-lowering effect mediated by AMPK signaling pathway 
but not involved Sirt1. 
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Figure 3: M-F4 increases AMPK phosphorylation but did not alter Sirt1 expression. 
 
The protein expression levels (A) and the TG levels (C) in C2C12 myotube which were 
treated with 100 μg/mL M-F4, and per-stimulated with or without the 15μM BML-275 
and 1mM AICAR. Quantified phosphorylation levels of AMPK(B). The protein 
expression levels (D) and the TG levels (E) in C2C12 myotube which treated with or 
without 25 μM sirtinol. *; p < 0.05, **; p < 0.01. n.s.; not significantly different. 
2-3 PPARα was involved in the AMPK signaling pathway which caused the TG-
lowering effect by M-F4. 
As a master regulator of cellular energy homeostasis, AMPK has a lot of 
relative substrates. PPARα and SREBP1 are importance targets in lipid metabolism 
related to AMPK. Overexpression of PPARα in the skeletal muscle increases the 
expression of genes for fatty acid uptake and oxidation[23]. SREBP-1 is a transcription 
factor of lipid metabolism involved in the synthesis of fatty acids and cholesterol[24]. 
Considering whether those two targets were involved in this triglyceride reducing 
effect, we used the real-time PCR to measure the mRNA level in myotubes pre-
treatment with 100 μg/mL M-F4 for 24 hr. In the result, PPARα was increased 
significantly by M-F4 stimulated. PPARα expression was increased by M-F4, while M-
F4 did not change expression levels of SREBP1 (Fig 4A). This triglyceride reducing effect 
probably mediated by augment of lipid oxidation through PPARα. GW6471 is PPARα 
specific antagonist[25]. We use Gw6471 as a PPARα inhibitor to treat cells. In the 
triglyceride measurement, the reducing effect caused by M-F4 was relieve when 
treated by 25μM Gw6471 (Fig 4B). 
 (A) 
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(B)  
 
 
Figure 4: Effects of M-F4 on mRNA levels in the expression of AMPK-related genes. 
Relative mRNA expression of metabolism-related genes in the C2C12 myotubes were 
treated with M-F4 or vehicle. Gene transcription of PPARα and SREBP1 (A) were 
normalized for GAPDH. The TG level in C2C12 myotube stimulated by M-F4 with or 
without Gw6471 (B). Data are expressed as the mean ± SD; n = 3. *p < 0.05 and **p < 
0.01 vs. the control.  
 
 
2-4 PPARα and its downstream targets mediate the TG and NEFA reducing effect 
caused by M-F4. 
In the PPARα signal pathway, a lot of downstream genes were concerned to be 
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involved (Fig 5A). PPAR gamma coactivator 1-alpha (PGC-1α) is a regulator of 
mitochondrial biogenesis and function, but in our experiment, PGC1α were not 
activated by M-F4. Carnitine palmitoyl transferase1 (CPT1b) which considered to be 
the gene that controlled fatty acid mitochondrial β-oxidation were mightily activated 
in 24hr by M-F4 stimulated. Considering the genes involved in lipid oxidation, the 
expression of ACO, MCAD and mtTFA were slightly increased following M-F4 stimulate, 
but there were no significant differences. Mitochondrial uncoupling protein 2 (UCP2) 
gene expression was increased in myotubes of M-F4 treated with statistically 
significant.  
M-F4 led the increasing trends of PPARα, CPT1b and UCP2 were mitigated when 
treated with Gw6471 (Fig 5B). This result was consistent with our expectation that 
CPT1b and UCP2 were the downstream targets of PPARα to reduce triglyceride level. 
CPT1b is a rate-limiting enzyme on the mitochondrial outer membrane, governing 
long-chain fatty acid entry into mitochondria. UCPs increase the proton conductance 
of the mitochondrial inner membrane, eventually promote fatty acid oxidation in the 
mitochondria. Therefore we conjecture the lipid reducing the effect of M-F4 not only 
reveal in triglyceride but also in the fatty acid. In figure 5C, we measure the non-
essential fatty acid in the myotubes, the result showed that M-F4 assuredly decreased 
the NEFT level and decreasing tendency alleviated by Gw6471 intervening.  
 
 
 
 
 
15 
 
 (A)  
 
(B)                                                                         
 
(C) 
0
0.5
1
1.5
2
PGC1α CPT1b ACO MCAD mtTFA UCP2
m
R
N
A
 e
x
p
re
s
s
io
n
Control
M-F4
* 
** 
* 
 
 
16 
 
 
Figure 5: PPARα and its downstream targets mediate the TG and NEFA reducing effect 
caused by M-F4. 
(A)Relative mRNA expression of PPARα-related genes in the C2C12 myotubes 
stimulated by M-F4. C2C12 myotubes were stimulated by M-F4 (100 μg/mL) and 
treated with or without Gw6471. The mRNA expression (B), and non-esterified fatty 
acid (C) in the C2C12 myotube stimulated by M-F4 with or without Gw6471 (Gw). Data 
are expressed as the mean ± SD. *;p < 0.05, **;p < 0.01 vs. the control. 
 
 
2-5 PPARα was the downstream target of AMPK signal pathway and involved in TG 
and NEFA reducing effect caused by M-F4. 
According to some papers, the relationship between AMPK and PPARα was a kind of 
complicated. In most cases, AMPK was the upstream target of PPARα, but in some 
special cases, PPARα was the upstream one. In the WB result, the level of p-AMPK was 
increased by M-F4 stimulated, and this increasing trend did not change in presence of 
Gw6471, but reduced in presence of BML-275(Fig 5A). On the other side, the PPARα 
increasing level induced by M-F4 reduced not only intervened by Gw6471 but also by 
BML-275. Those results shown that PPARα is the downstream target of AMPK signal 
pathway in this TG and NEFA reducing effect caused by M-F4. 
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Figure 6: PPARα was the downstream target of AMPK signal pathway. 
C2C12 myotubes were stimulated by M-F4 (100 μg/mL) and treated with or without 
25μM Gw6471 and 15μM BML-275. The proteins were examined by western blotting 
analysis to check PPARα and phosphorylation and total levels of AMPK. 
. 
The proposed scheme for M-F4-stimulated signaling pathway in C2C12 myotubes was 
shown in Figure7. In the lipid metabolism process, M-F4 is primarily phosphorylated 
AMPK-Thr172, but does not involve Sirt1 pathway. Then mediated by PPARα and its 
downstream targets CPT1b and UCP2, ultimately leading to improve lipid metabolism 
characterized by TG and NEFA reducing. 
p-AMPK 
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Figure 7: Proposed scheme for M-F4-stimulated signaling pathway in C2C12 myotubes. 
In the lipid metabolism process, M-F4 is primarily dependent on AMPK activation. Then 
mediated by PPARα, CPT1b and UCP2, ultimately lead to amplifying the β-oxidation. 
Simultaneously induce fatty acid and triglyceride level reduce in the C2C12 myotubes. 
 
 
 
3 Discussion 
The aim of this research is to find the lipid lowering fraction in Citrus sudachi, and 
investigate its mechanism. We found that the sudachi peel crude extract could reduce 
intracellular TG level of C2C12 cells. Moreover, M-F4, a fraction obtained from the 
sudachi peel extract, reduce triglyceride of C2C12 cells. In this lipid-lowering effect, 
the PPARα and its downstream targets were activated by AMPK, suggesting that M-F4 
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improved the lipid metabolism characterized by TG and NEFA reducing, via activated 
AMPK and mediated by PPARα and its downstream targets CPT-1b and UCP2. 
Several reports have demonstrated that citrus played important roles in regulating 
glucose and lipid metabolic disorders[26-28]. In our previous study, the peel dry 
powders of Citrus sudachi inhibited the rising trend of blood glucose and fatty acid in 
human. We hypothesized that if this fatty acid rising trend inhibiting effect caused by 
TG consumption increasing in blood, the sudachi peel dry powders probably could 
reduce intracellular TG level in C2C12 cells. In the extracting process, we got five 
fractions of methanol sudachi peel extractions. Among those of fractions, the M-F4 
had the strongest effect on triglyceride reducing effect in both myoblasts and 
myotubes. Because the C2C12 myotubes were differentiated cells and have mature 
cell function, we chose the myotubes to use in the next experiments which was more 
close to the skeletal muscle in vivo. 
In order to find out the proper condition for the mechanism research, we tested a 
series of varied concentration (1μg/mL - 500 μg/mL) and stimulation time (2 hr- 48hr) 
(Supplement 1(A)). In the concentration-variable experiment, while the triglyceride 
reduces the effect of M-F4 as 500 μg/mL was most intensely, but considering about 
the cell viability result we got in MTT assay (Supplement 2), we chose concentration 
as 100 μg/mL in the stimulation process. In the stimulation time-variable experiment, 
the reduction effect started from 2 hr slightly and became remarkably in 24 
hr(Supplement 1(B)). We chose concentration as 100 μg/mL for 24 hr stimulation in 
the next step of study. Since the myotubes were differentiated by grown in DMEM 
 
 
20 
 
supplemented with 2% horse serum for 1 week, the differentiation also in progress 
during our stimulation experiment periods. We intended the control group at every 
time point to avoid result changed.  
AMPK is an important metabolism target with diverse functions in many cell types, 
include regulate lipid and carbohydrate metabolism in skeletal muscle[29]. We first 
hypothesized that sudachi peel extract reduces triglyceride effect is likely to be related 
to AMPK. In addition, Sirt1 always has a complicated relationship with AMPK in many 
metabolic regulate fields. But in our Western Blotting assay, only AMPK related 
proteins were activated obviously. In the following experiment, sirtinol and AICAR 
were used to intervene the expression of Sirt1 and AMPK, the results were consistent 
with previous ones. It means that AMPK should be involved in the TG reducing effect 
caused by M-F4, and this effect may depended on some other AMPK- related target 
but not Sirt1. 
PPARs are ligand-activated transcription factors including PPARα, PPARγ and PPARδ 
(also known as PPARβ) belonging to the nuclear receptor family. The PPARs act as fatty 
acid sensors to control many metabolic programs that are essential for systematic 
energy homeostasis[10, 30]. As shown in the result, M-F4 exerted the triglyceride 
reducing effect by activating PPARα. This is supported by some studies, which 
confirmed the role of PPARα in fatty acid catabolism in peripheral tissues[23]. There 
also reported that naringenin treatment lowers triglyceride and cholesterol in plasma 
and liver by increasing the PPARα expression in rat liver[31]. PPARα null mice have 
decreased expression of cardiac fatty acid oxidation genes and decreased rates of fatty 
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acid oxidation, but maintain normal cardiac function[32, 33]. PPARα/γ may exert the 
synergic inhibitory effects on fatty acid synthesis by controlling the expressions of the 
transcription factor SREBP-1c[34], though this does not correspond with our results. 
The target genes regulated by PPARα and involved in lipid metabolism and obesity 
include PGC1α, CPT1b, MCAD, UCP2, ACO and mtTFA[35-39]. PGC1α has been 
implicated in increasing the oxidation of fatty acids via increasing mitochondrial 
capacity and function, making this co-factor a key candidate for the treatment of 
lipotoxicity recently[35]. Unexpectedly, the expression level of PGC1α was declined by 
stimulation, which is probably because PGC1α activity is also altered via AMPK and 
Sirt1 pathways[6]. Some reports showed that synergistic activation of the CPT1b gene 
is promoted by the heterodimer of nuclear receptors PPARα-RXRα[36]. Slight increases 
in CPT1 expression in muscle can recover insulin sensitivity and reduced lipid 
accumulation[40, 41]. Our current results exactly suggest that TG reducing effect is 
mediated by augment of lipid oxidation through the PPARα-CPT1b pathway. UCP2 is 
expressed and functionally active in both central and peripheral tissues involved in 
glucose and lipid metabolism[42]. It was reported that obesity could be treated by 
promoting the activity of native UCP in muscle[43]. There also reported that UCP2 
gene expression was significantly increased in skeletal muscle of mice which improved 
glucose and lipid metabolism[6]. Molecular mechanisms how M-F4 exerts the lipid-
lowering effects we propose is summarized in Fig. 7. 
We considered if M-F4 improved the lipid metabolism by reducing TG only, or it could 
effect on other lipid substance. Consistent with our expectation, M-F4 improved the 
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lipid metabolism characterized by both TG and NEFA reducing in C2C12 myotubes.  
Conclusion 
In summary, our study is the first to demonstrate that sudachi peel methanol extract 
reduces triglyceride and fatty acid level in the skeletal muscle cell. Additionally, our 
findings suggest that M-F4 improves the lipid metabolism through AMPK, PPARα and 
their downstream targets, CPT-1b and UCP2. Furthermore, these observations indicate 
that this extract may be useful for preventing obesity and diabetes-related diseases. 
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Supplement 
(A)  
 
(B) 
 
 
Supplement 1 : 
Triglyceride content in cellular lysates is reported in the graph. C2C12 myotube were 
treated by M-F4 with (A) different concentration (0.1 μg/mL~500 μg/mL) and (B) 
different periods (2 hr-24 hr). *;p < 0.05, **;p < 0.01 vs. the control. 
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Supplement 2: 
The effects of M-F4 on cell viability. 
Viability of C2C12 cells were determined by MTT assay 24 (circle), 48 (triangle), or 72 
(square) hr after exposure to indicated concentration of M-F4, respectively. **; p<0.01 
vs vehicle control. 
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